Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
In retirement, choosing between Sp500 and Total Market matters. This guide outlines criteria to select the better fit for your horizon and risk profile.
28,409 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Uber reports a landmark milestone as Uber One membership tops 50 million, with members driving half of Mobility and D...
Investors are weighing growth, profitability, and risk after the newest earnings release. Here’s a practical, plain-l...
Inflation and eroding wages are reshaping Argentina’s shopping carts, with meat markets throttled by a broad-based ar...
Qualcomm surges 12%, Skyworks rallies 9%, and Qorvo climbs 7% as a narrowing set of mobile-chip winners outpaces broa...
Yatsen's Q1 2026 results are a pivotal signal for the year ahead. This analysis breaks down the earnings narrative, h...
Netflix reports a strong Q1 2026, lifting free cash flow guidance and accelerating ad revenue. Analysts see a path to...
Applied Optoelectronics has rocketed higher in 2026, delivering a 439% year-to-date gain as hyperscale AI data center...
A software engineer stands on the cusp of a potential million tax-free gain startup under QSBS rules, but a five-year...
A high-profile leadership overhaul at CBS News exposes the risks of aggressively rewriting a legacy brand as audience...
Solstice’s Ryan Day argues that durable DeFi yields must be grounded in real cash flows and risk controls, not hype a...
An AI-driven forecast linked to Sam Altman points to a sharp Bitcoin rally by year-end 2026, with specific price band...